Stock 6160 BEIGENE, LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Company BeiGene, Ltd. Hong Kong S.E.

Equities

6160

KYG1146Y1017

Biotechnology & Medical Research

Market Closed - Hong Kong S.E.
Other stock markets
 01:38:07 05/07/2024 pm IST 		5-day change 1st Jan Change
88.6 HKD +2.84% Intraday chart for BeiGene, Ltd. +2.78% -19.53%
01/07 Asian Equities Traded in the US as American Depositary Receipts Open Week on Flat Note MT
26/06 Beigene Insider Sold Shares Worth $445,070, According to a Recent SEC Filing MT

Business Summary

BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.

Number of employees: 10,000

Sales per Business

USD in Million2022Weight2023Weight Delta
Pharmaceutical Products
100.0 %
1,416 100.0 % 2,459 100.0 % +73.65%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
45.9 %
503 35.5 % 1,128 45.9 % +124.46%
China
44.8 %
840 59.3 % 1,102 44.8 % +31.18%
Europe
8.2 %
-- 202 8.2 % -
Rest of World
1.1 %
73 5.2 % 27 1.1 % -63.70%

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 1,244,457,968 1,222,239,074 ( 98.21 %) 0 98.21 %

Shareholders

NameEquities%Valuation
AMGEN INC.
19.79 %
246,269,426 19.79 % 2 787 M $
Capital Research & Management Co. (International Investors)
8.313 %
103,421,157 8.313 % 1 171 M $
John Oyler
6.149 %
76,503,298 6.149 % 866 M $
HHLR Advisors Ltd.
6.076 %
75,588,463 6.076 % 856 M $
Xiao Dong Wang
1.673 %
20,812,777 1.673 % 236 M $
Capital International, Inc.
0.8888 %
11,057,735 0.8888 % 125 M $
GF Fund Management Co., Ltd.
0.6135 %
7,632,000 0.6135 % 86 M $
China Asset Management Co., Ltd.
0.2857 %
3,555,000 0.2857 % 40 M $
Donald Glazer
0.2185 %
2,718,464 0.2185 % 31 M $
Invesco Great Wall Fund Management Co. Ltd. (Invt Mgmt)
0.2146 %
2,670,100 0.2146 % 30 M $
NameEquities%Valuation
Penghua Fund Management Co., Ltd.
6.337 %
7,290,681 6.337 % 122 M $
Wanjia Asset Management Co., Ltd.
4.489 %
5,165,018 4.489 % 87 M $
ICBC Credit Suisse Asset Management Co., Ltd.
4.041 %
4,648,832 4.041 % 78 M $
Bank of China Investment Management Co., Ltd.
2.640 %
3,037,160 2.640 % 51 M $
Bosera Asset Management Co., Ltd.
2.328 %
2,678,498 2.328 % 45 M $
Abu Dhabi Investment Authority (Investment Management)
2.092 %
2,407,263 2.092 % 40 M $
Taiping Life Insurance Co. Ltd. (Investment Portfolio)
2.092 %
2,407,263 2.092 % 40 M $
China International Capital Corp. Ltd. (Invt Management)
1.799 %
2,069,546 1.799 % 35 M $
GF Fund Management Co., Ltd.
1.585 %
1,823,581 1.585 % 31 M $
Guangxi Tongfu Kexing Investment Management LP
1.255 %
1,444,358 1.255 % 24 M $
NameEquities%Valuation
Baker Bros. Advisors LP
11.04 %
10,568,897 11.04 % 1 573 M $
Capital Research & Management Co. (International Investors)
7.382 %
7,064,428 7.382 % 1 052 M $
HHLR Advisors Ltd. (Cayman Islands)
5.409 %
5,176,906 5.409 % 771 M $
PRIMECAP Management Co.
5.227 %
5,001,839 5.227 % 745 M $
Baillie Gifford & Co.
3.896 %
3,728,730 3.896 % 555 M $
Temasek Holdings Pte Ltd.
3.150 %
3,014,171 3.150 % 449 M $
T. Rowe Price International Ltd.
2.117 %
2,026,094 2.117 % 302 M $
Fidelity Management & Research Co. LLC
1.756 %
1,680,463 1.756 % 250 M $
BlackRock Advisors LLC
0.9467 %
905,962 0.9467 % 135 M $
Capital International, Inc.
0.8969 %
858,364 0.8969 % 128 M $

Company contact information

BeiGene Ltd.

94 Solaris Avenue Camana Bay

KY1-1108, George Town

+345-949-4123

http://www.beigene.com
address BeiGene, Ltd.(6160)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per region

Ratings for BeiGene, Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
147 USD
Average target price
267 USD
Spread / Average Target
+81.59%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+16.61% 122B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+17.75% 112B
ARGENX SE Stock argenx SE
+17.23% 25.91B
BIONTECH SE Stock BioNTech SE
-24.11% 19.33B
GENMAB A/S Stock Genmab A/S
-18.56% 16.17B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-47.75% 14.65B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+57.35% 14.34B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.62% 14B
INSMED INCORPORATED Stock Insmed Incorporated
+125.88% 11.29B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. BGNE Stock
  4. 6160 Stock
  5. Company BeiGene, Ltd.